BEHIND THE SCIENCE

 

Culture-based production of cell-derived biologics and whole-cell therapies dominates the biopharmaceutical market. In 2019, seven of the ten best-selling drugs were biologics.¹

 

Pharmaceutical organizations are developing a wide range of new culture-based therapeutics and techniques. They produce a dynamic range of biologically relevant byproducts, from therapeutic antibodies and proteins to recombinant hormones and clotting factors. Stem cell and regenerative medicine are also emerging fields that employ whole-cell therapies. These biologically-based therapies, engineered from living mammalian cells, will only increase as scientists' understanding of diseases continues to expand.

 

The need for scaling up cell culture platforms continues to increase as biologically-derived therapies progress to the clinical trial stages. Many biologically-based therapies that harvest cell culture byproducts continue to rely on adherent cell lines as a reliable means to produce consistent yields. Many facilities expanding highly specialized cell lines for use in therapies require scale up that avoids shear-damage and stress that can occur when using agitators.² For this reason, smaller and mid-size facilities have an increased need for incubator space.

 

Large capacity CO₂ incubators provide reliable bioproduction methods. They allow space maximization for multi-stacked flasks, roller bottle apparatuses, orbitals, shakers and more gentle agitation machinery for biological expression.

 

PHCbi brand cell culture equipment represents over fifty years of expertise in engineering and design. The PHCbi brand CytoGrow ReachIn MCO-80ICL-PA delivers a precise and accurate cell culture environment for facilities adhering to good manufacturing practices (GMP), from pilot to mid-scale cell culture to scale-up applications.

 

To learn more about the CytoGrow ReachIn CO₂ incubator, visit https://www.phchd.com/us/biomedical/incubators/CO2incubators/mco-80ic.